Dopamine agonists in schizophrenia: a review

@article{Benkert1995DopamineAI,
  title={Dopamine agonists in schizophrenia: a review},
  author={O. Benkert and F. M{\"u}ller-Siecheneder and H. Wetzel},
  journal={European Neuropsychopharmacology},
  year={1995},
  volume={5},
  pages={43-53}
}
Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology. Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a negative feedback… Expand
Dopamine in schizophrenia.
TLDR
The ongoing and future work on the precise role of DA in schizophrenia should focus on first-episode/admission neuroleptic-naive schizophrenic patients, as such studies represent the best opportunity of finding out specific changes in the dopaminergic pathways and relating them in a meaningful way to various dimensions of psychopathology seen in schizophrenia patients. Expand
Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
TLDR
Strategies for obtaining ideal effective antipsychotics with reduced side effects are considered in this short review with respect to the intrinsic efficacies and affinities of the partial agonists, based on thepartial agonist concept. Expand
Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review.
Schizophrenia has been historically characterized by the presence of positive symptomatology, however, decades of research highlight the importance of cognitive deficits in this disorder. At present,Expand
The role of dopamine in the pathophysiology and treatment of apathy.
TLDR
There are a priori reasons for considering dopamine in the treatment of disorders of diminished motivation, and the development of novel paradigms which are able to objectively dissect motivational dysfunction are well positioned to quantify the effect of specific classes of dopaminergic medication on reward- and effort-based decision making in apathy. Expand
Neurobiological Background for the Development of New Drugs in Schizophrenia
TLDR
Research in the antipsychotics field has developed also by exploring pathways that are beyond the spectrum of clozapine, and among the most promising mechanisms are those based on the glutamatergic hypothesis of schizophrenia. Expand
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
TLDR
Compounds possessing “balanced” 5- HT1A receptor agonism and D2 antagonism and, in some cases, combined with other beneficial properties, such as 5-HT2A receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a lower propensity to elicit EPS or metabolic dysfunction. Expand
Discovery and preclinical evaluation of novel dopamine partial agonists as antipsychotic agents
Abstract Antagonism of DA D2 receptors is thought to be the primary molecular mechanism for the efficacy of existing antipsychotic agents. This efficacy is believed to arise from blockade of DA D2Expand
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
TLDR
An update and critical review of the pharmacology and clinical profiles of current antipsychotic drugs and drugs acting on novel targets with potential to be therapeutic agents in the future is provided. Expand
Pharmacology of "atypicality" of antipsychotic drugs: status and perspectives
Summary "Atypical" antipsychotics are antagonists at serotonin 5-HT2A and dopamine d2 receptors. However, their effects on negative symptoms and cognitive deficits remain modest and they disruptExpand
A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications
TLDR
In patients already on antipsychotic drugs, the addition of l-dopa can be beneficial, and Dopamine agonists merit further consideration as adjuncts to antipsychotics drugs in the treatment of schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression.
TLDR
Current evidence from pilot studies suggests that dopamine autoreceptor agonists like roxindole may produce a minor to moderate improvement of symptoms like affective flattening, depressed mood, alogia, and avolition, possibly by stimulation of supersensitive postsynaptic dopamine receptors. Expand
Dopamine autoreceptor agonists in the treatment of schizophrenic disorders
  • H. Wetzel, O. Benkert
  • Psychology, Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1993
TLDR
Current evidence from open clinical trials suggests that dopamine autoreceptor agonists may produce a minor to moderate improvement of symptoms like affective flattening, depressed mood, alogia and avolition. Expand
Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.
Partial dopamine agonists showing high affinity but low efficacy at D2 receptors can act as dopaminergic "buffers," reducing dopaminergic activity when it is excessive, and promoting it when reduced.Expand
Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
TLDR
A clinical investigation of EMD 49980 in affective disorders and in schizophrenia with depression or anergia should be performed, in view of the only moderate antipsychotic efficacy in acute schizophrenia. Expand
B-HT920 - A Novel Dopamine Autoreceptor Agonist in the Treatment of Patients with Schizophrenia
In an open clinical trial the azepine derivative B-HT 920 was administered to patients with schizophrenia, paranoid type (according to ICD-9 and DSM-III criteria), in order to examine whetherExpand
Clinical effects of apomorphine in schizophrenia.
TLDR
A placebo-controlled study of acute and chronic schizophrenics in which videotaped interviews were blindly rated found no specific therapeutic effect was demonstrated for apomorphine other than a reduction in anxiety in acute schizophrenics. Expand
Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies.
TLDR
Preclinical and clinical studies suggest that administration of low doses of conventional dopamine agonists such as apomorphine can inhibit the activity of some dopaminergic neurons and be of therapeutic use in the treatment of excited psychotic states and a variety of abnormal movement disorders. Expand
B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia
TLDR
The clinical results suggest that activation of D2 receptors was related to partial amelioration of the negative symptoms of schizophrenia and are consistent with a hypothesis that decreased dopaminergic activity may be related to the etiology of negative Symptoms of schizophrenia. Expand
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
TLDR
Results indicate that an active though nonsedating dose of apomorphine does not ameliorate symptoms of schizophrenia or tardive dyskinesia. Expand
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
TLDR
The cloning of a gene that encodes a dopamine receptor gene that has high homology to the human dopamine D2 and D3 receptor genes is reported, which suggests the existence of other types of dopamine receptors which are more sensitive to clozapine. Expand
...
1
2
3
4
5
...